Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2020 October;111(5) > Minerva Medica 2020 October;111(5):386-94

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  ACUTE LEUKEMIAS IN 2020: STATE OF THE ART Freefree

Minerva Medica 2020 October;111(5):386-94

DOI: 10.23736/S0026-4806.20.07016-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia

Raffaele PALMIERI 1, Francesco BUCCISANO 1 , Luca MAURILLO 1, Maria I. DEL PRINCIPE 1, Giovangiacinto PATERNO 1, Adriano VENDITTI 1, Giovanni MARTINELLI 2, Claudio CERCHIONE 2

1 Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy; 2 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing risk-adapted treatment strategies. Nevertheless, to improve further the outcome of AML patients we are still in need of accurate methods to explore the quality of response and to adequately discriminate patients who are likely to relapse over time from those who are in deep and stable remission. In this view, is it well established that measurement of leukemic cells surviving chemotherapy (called measurable residual disease, MRD) during the course of treatment may be a reliable biomarker in predicting relapse. Detection of MRD relies on highly sensitive techniques, such as quantitative polymerase chain reaction and multiparametric flow cytometry, which, due to their levels of specificity and sensitivity, are increasingly included in the decision-making process of AML treatment. In the present manuscript, we will review the current techniques of MRD investigation and their clinical contribution to AML management.


KEY WORDS: Neoplasm, residual; Flow cytometry; Leukemia, myeloid, acute

inizio pagina